The Claim
In older adults with ischemic systolic heart failure, daily administration of 10 mg rosuvastatin for 32.8 months results in no significant difference in the incidence of newly diagnosed diabetes or in the progression of serum creatinine levels compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In older adults with a type of heart failure, taking 10 mg of rosuvastatin daily for about 2.7 years does not change the rate of new diabetes cases or kidney function decline compared to taking a placebo.
See the scientific wording
In older adults with ischemic systolic heart failure, daily 10 mg rosuvastatin does not significantly reduce the incidence of newly diagnosed diabetes or worsen renal function, with no difference in serum creatinine progression or new diabetes cases between treatment and placebo groups over 32.8 months.
Rosuvastatin lowers cholesterol and reduces inflammation in the liver and blood vessels, which improves blood flow and protects the heart, but it does not change how the body processes sugar or how the kidneys filter waste.
What the research says
1 studyStudy: Rosuvastatin in older patients with systolic heart failure.
The study gave older heart failure patients rosuvastatin for nearly three years and found no signs it caused more diabetes or kidney problems compared to a placebo. So, it didn’t make those issues worse.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.